Skip to main content
OpenTrials
Completed

NCT Number: NCT01698112

Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?

This project is a clinical intervention trial that will determine the role of a functional food, flaxseed, on the control of blood glucose levels in people with pre-diabetes. People with pre-diabetes have high blood glucose levels since their cells do not respond to insulin as they should. Over time, people with pre-diabetes may progress to type 2 diabetes and have increased risk for heart and kidney diseases. Although the long-term complications associated with type 2 diabetes are well-recognized, clinicians and researchers are now realizing that some long-term damage to the body, especially the heart and circulatory system, may already be occurring during pre-diabetes. Consequently, clinicians are recognizing that glucose control, through diet, exercise and, if necessary, medications, is as important for people with pre-diabetes as it is for people with type 2 diabetes.

Standard treatments for pre-diabetes are glucose control through diet, exercise, and drugs. A possible treatment that could be added to the standard treatments is intake of flaxseed. Few studies have looked at the effect of flaxseed intake on glucose control and those that have enrolled people with type 2 diabetes. To date, no studies have reported flaxseed's affect on controlling blood glucose in people with pre-diabetes. Therefore, more research is needed to determine if flaxseed is an effective means of controlling glucose levels in people with pre-diabetes.

This study will help determine whether or not eating modest amounts of flaxseed every day will improve blood glucose and insulin levels in overweight or obese men and postmenopausal women with pre-diabetes. It will also show if flaxseed intake will reduce the degree of inflammation they are experiencing.

If flaxseed consumption does help control blood glucose levels in people with pre-diabetes and reduce the degree of inflammation they are experiencing, it may help prevent or delay their progression to type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Colorado Colorado Springs, Colorado Springs, Colorado, United States

Loading trial locations.

About this study

Pre-diabetes is characterized by hyperglycemia due to ineffective insulin or 'insulin resistance'. Over time, people with pre-diabetes may progress to type 2 diabetes and experience complications including cardiovascular and peripheral vascular disease, hyperlipidemia, retinopathy, neuropathy, and/or nephropathy. Conventional interventions for pre-diabetes are glucose control through diet, exercise, and, if necessary, medications. An efficient but still uncommon adjunct intervention is flaxseed supplementation. Since few studies have examined the affect of flaxseed supplementation on type 2 diabetes and to date, no studies have reported flaxseed's influence on glycemic control in individuals with pre-diabetes, additional research is warranted. The objective of this study is to determine the affect of consuming flaxseed on fasting plasma glucose, insulin, fructosamine, adiponectin, fatty acid concentrations, serum interleukin-6 (hs-IL-6), C-reactive protein (hs-CRP), and urinary lignan excretion in overweight or obese men and postmenopausal women with pre-diabetes. This research will provide data for the strength of the relationship between regular flaxseed intake and biomarkers for pre-diabetes and glycemic control as well as adiponectin values and markers of inflammation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • (1) no unresolved health conditions (e.g. if high blood pressure is present it is under control due to diet and/or medications) and no diagnosis of type 2 diabetes;
  • (2) non-smoking status;
  • (3) no regular history of flaxseed or flaxseed oil supplement or fish oil supplement intake;
  • (4) no regular history of sunflower seed intake (1/8 cup < 1 time per week); fish intake (< 12 ounces of fish/week); and soy intake (1 serving of soy < 3 times per week; 1 serving of soy equals 3 oz. tofu, 8 oz. soy milk, ¼ c. soy nuts or ½ c. edamame);
  • (5) willingness to follow study protocol, scheduling, and testing location;
  • (6) body mass index (BMI) of 25-34.9 kg/m2;
  • (7) men or postmenopausal women (no menstrual cycle for > 6 months; women who have had a hysterectomy are eligible for participation) ages 50-65 years;
  • (8) fasting glucose value of > 100 and < 126 mg/dL.

Exclusion criteria

  • (1) unresolved health conditions or diagnosis of type 2 diabetes;
  • (2) smokes;
  • (3) regular history of flaxseed or flaxseed oil supplement or fish oil supplement intake;
  • (4) regular history of sunflower seed intake (1/8 cup < 1 time per week); fish intake (< 12 ounces of fish/week); and soy intake (1 serving of soy < 3 times per week; 1 serving of soy equals 3 oz. tofu, 8 oz. soy milk, ¼ c. soy nuts or ½ c. edamame);
  • (5) unwillingness to follow study protocol, scheduling, and testing location;
  • (6) body mass index (BMI) less than 25 or greater than 34.9 kg/m2;
  • (7) premenopausal women;
  • (8) men or postmenopausal women less than 50 or greater than 65 years of age;
  • (9) fasting glucose value of less than 100 or greater than 126 mg/dL.

Treatment and study plan

Flaxseed High Dose

Dietary Supplement

26 gram flaxseed intervention

Flaxseed Low Dose

Dietary Supplement

13 grams flaxseed

Primary outcomes

  1. Fasting glucose

    Time frame: beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

  2. Fasting insulin

    Time frame: beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

  3. Fasting fructosamine

    Time frame: beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

Secondary outcomes

  1. C-reactive protein

    Time frame: beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

  2. interleukin 6

    Time frame: beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

  3. adiponectin

    Time frame: beginning and end of each 12-week intervention (start of 1st week and end of 12th week)

Sponsors and collaborators

Lead sponsor

University of Colorado, Colorado Springs

Other

Registry information

Important dates

Study start
2006
Primary completion
2009
Study completion
2009
First posted
Oct 2, 2012
Registry last updated
Oct 2, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.